Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nanobiotix S.A. filings document foreign private issuer reporting for a late-stage clinical biotechnology company developing nanoparticle-based therapeutic platforms. Recent Form 6-K reports furnish press-release exhibits covering JNJ-1900 (NBTXR3) clinical and regulatory disclosures, Nanoprimer preclinical data, operating and financial updates, and responses to corporate-status speculation.
The filing record also documents capital-structure and governance information, including share capital, theoretical and exercisable voting rights reported under French market rules, material agreements tied to development and commercialization collaborations, and foreign private issuer status on Form 20-F for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix S.A. filed a Form 6-K to share that it has been included in the Euronext Tech Leaders segment and added to the Euronext Tech Leaders Index. This Euronext initiative highlights innovative, high-growth European technology companies and aims to increase their visibility with international investors.
The company describes itself as a late-stage clinical biotechnology business pioneering physics-based nanotherapeutic approaches for cancer and other major diseases. Headquartered in Paris and listed on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix owns more than 30 umbrella patents across three nanotechnology platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix S.A. has entered an underwriting agreement for a global equity offering combining U.S. and European tranches plus long-dated pre-funded warrants. The deal includes 225,373 ADSs in the United States at $38.98 per ADS and 1,959,289 ordinary shares in Europe at €33.60 per share, alongside 345,099 pre-funded warrants, each exercisable for one ordinary share at €0.03.
The underwriters also exercised a U.S. over-allotment option for 33,805 additional ADSs at $38.98 per ADS, with the overall global offering expected to close on or about May 26, 2026. The pre-funded warrants are exercisable until May 26, 2036, subject to a Beneficial Ownership Limitation initially set at 9.99% of outstanding ordinary shares, with possible increases up to 19.99% of shares and, for French foreign direct investment purposes, up to 24.99% of voting rights, subject to regulatory conditions.
Nanobiotix has closed a global equity offering raising aggregate gross proceeds of about $100 million (approximately €86.1 million). The financing comprised 2,218,467 new ordinary shares, including ADSs and Additional ADSs, and 345,099 pre-funded warrants.
The subscription price was €33.60 per ordinary share, equal to an ADS offering price of $38.98, reflecting a 14.92% discount to the recent volume-weighted average share price. Net proceeds are earmarked mainly to advance Nanoprimer and other platforms, support JNJ-1900 (NBTXR3), and for general corporate purposes, and are expected to fund operations into 2029.
Nanobiotix S.A. completed the full exercise of underwriters’ over-allotment option in its global equity offering, bringing aggregate gross proceeds to approximately $100 million (about €86.1 million) before fees and expenses. The option exercise adds 33,805 Additional ADSs at $38.98 each, corresponding to €33.60 per ordinary share. In total, the Global Offering comprises 2,218,467 ordinary shares, including 259,178 in ADS form, plus 345,099 pre-funded warrants. Nanobiotix plans to allocate between 50-60% of net proceeds to its Nanoprimer and other platforms, less than 10% to JNJ-1900 (NBTXR3), and 30-40% to general corporate purposes. The company states that, with this financing and existing cash, it expects to fund operations into 2029.
Nanobiotix S.A. is conducting a global offering of 2,184,662 ordinary shares and 345,099 pre-funded warrants, consisting of a U.S. offering of 225,373 ADSs (one ADS = one ordinary share) and a European offering of 1,959,289 ordinary shares plus 345,099 pre-funded warrants.
The public offering price is €33.60 per ordinary share (ADS price $38.98), and each pre-funded warrant is priced at €33.57 with an exercise price of €0.03 per ordinary share. Net proceeds are estimated at approximately €79.12 million (before expenses), and the underwriters have a 30‑day option to purchase up to 33,805 additional ordinary shares, which would increase estimated net proceeds to €80.89 million.
Shares outstanding were 48,410,068 ordinary shares as of December 31, 2025. The pre-funded warrants are not expected to trade on any exchange and contain beneficiary ownership caps that limit exercises above specified thresholds.
Nanobiotix S.A. priced an oversubscribed global follow-on offering raising expected gross proceeds of about €85.0 million (approximately $98.6 million) before fees, with potential to reach about €87.8 million if the over-allotment option is fully exercised.
The deal comprises 225,373 ADSs at $38.98 each in the U.S., plus 1,959,289 ordinary shares at €33.60 and 345,099 pre-funded warrants at €33.57 in Europe and other markets. Each pre-funded warrant can be exercised in cash for one share at €0.03 until May 26, 2036.
The company plans to allocate between 50-60% of net proceeds to its Nanoprimer and other platforms, less than 10% to JNJ-1900 (NBTXR3), and 30-40% to general corporate purposes, and expects its cash resources plus this raise to fund operations into 2029. Illustrative tables show dilution for non-participating holders, with a 1% stake falling to about 0.95% on a fully diluted post-transaction basis and equity per share improving from -€1.75 to around -€1.66.
Nanobiotix S.A. priced an oversubscribed global follow-on offering raising expected gross proceeds of about €85.0 million (approximately $98.6 million) before fees, with potential to reach about €87.8 million if the over-allotment option is fully exercised.
The deal comprises 225,373 ADSs at $38.98 each in the U.S., plus 1,959,289 ordinary shares at €33.60 and 345,099 pre-funded warrants at €33.57 in Europe and other markets. Each pre-funded warrant can be exercised in cash for one share at €0.03 until May 26, 2036.
The company plans to allocate between 50-60% of net proceeds to its Nanoprimer and other platforms, less than 10% to JNJ-1900 (NBTXR3), and 30-40% to general corporate purposes, and expects its cash resources plus this raise to fund operations into 2029. Illustrative tables show dilution for non-participating holders, with a 1% stake falling to about 0.95% on a fully diluted post-transaction basis and equity per share improving from -€1.75 to around -€1.66.
Nanobiotix S.A. priced an oversubscribed global follow-on offering raising expected gross proceeds of about €85.0 million (approximately $98.6 million) before fees, with potential to reach about €87.8 million if the over-allotment option is fully exercised.
The deal comprises 225,373 ADSs at $38.98 each in the U.S., plus 1,959,289 ordinary shares at €33.60 and 345,099 pre-funded warrants at €33.57 in Europe and other markets. Each pre-funded warrant can be exercised in cash for one share at €0.03 until May 26, 2036.
The company plans to allocate between 50-60% of net proceeds to its Nanoprimer and other platforms, less than 10% to JNJ-1900 (NBTXR3), and 30-40% to general corporate purposes, and expects its cash resources plus this raise to fund operations into 2029. Illustrative tables show dilution for non-participating holders, with a 1% stake falling to about 0.95% on a fully diluted post-transaction basis and equity per share improving from -€1.75 to around -€1.66.
Nanobiotix S.A. reports that trading in its ordinary shares on the regulated market of Euronext Paris has resumed as of 3:30 p.m. Paris time / 9:30 a.m. New York time on May 21, 2026.
Trading had been halted earlier that day at the company’s request in connection with a previously announced global securities offering. This global offering includes a U.S. public offering of American Depositary Shares, each representing one ordinary share with a nominal value of €0.03, and an international offering of ordinary shares and pre-funded warrants to qualified investors in Europe and certain other countries outside the United States and Canada.
Nanobiotix S.A. reports that trading in its ordinary shares on the regulated market of Euronext Paris has resumed as of 3:30 p.m. Paris time / 9:30 a.m. New York time on May 21, 2026.
Trading had been halted earlier that day at the company’s request in connection with a previously announced global securities offering. This global offering includes a U.S. public offering of American Depositary Shares, each representing one ordinary share with a nominal value of €0.03, and an international offering of ordinary shares and pre-funded warrants to qualified investors in Europe and certain other countries outside the United States and Canada.
Nanobiotix S.A. reports that trading in its ordinary shares on the regulated market of Euronext Paris has resumed as of 3:30 p.m. Paris time / 9:30 a.m. New York time on May 21, 2026.
Trading had been halted earlier that day at the company’s request in connection with a previously announced global securities offering. This global offering includes a U.S. public offering of American Depositary Shares, each representing one ordinary share with a nominal value of €0.03, and an international offering of ordinary shares and pre-funded warrants to qualified investors in Europe and certain other countries outside the United States and Canada.
Nanobiotix S.A. reports that trading of its ordinary shares on Euronext Paris is being temporarily halted at the company’s request. The halt is linked to a previously announced global equity financing that combines a U.S. public offering of American Depositary Shares with an international offering of ordinary shares and pre-funded warrants to qualified investors outside the United States and Canada.
The pause is intended to allow final allocation to investors and announcement of pricing for this global offering. Trading on Euronext Paris is expected to resume on May 21, 2026, at about 3:30 p.m. Paris time, which corresponds to 9:30 a.m. in New York.
Nanobiotix S.A. reports that trading of its ordinary shares on Euronext Paris is being temporarily halted at the company’s request. The halt is linked to a previously announced global equity financing that combines a U.S. public offering of American Depositary Shares with an international offering of ordinary shares and pre-funded warrants to qualified investors outside the United States and Canada.
The pause is intended to allow final allocation to investors and announcement of pricing for this global offering. Trading on Euronext Paris is expected to resume on May 21, 2026, at about 3:30 p.m. Paris time, which corresponds to 9:30 a.m. in New York.
Nanobiotix S.A. reports that trading of its ordinary shares on Euronext Paris is being temporarily halted at the company’s request. The halt is linked to a previously announced global equity financing that combines a U.S. public offering of American Depositary Shares with an international offering of ordinary shares and pre-funded warrants to qualified investors outside the United States and Canada.
The pause is intended to allow final allocation to investors and announcement of pricing for this global offering. Trading on Euronext Paris is expected to resume on May 21, 2026, at about 3:30 p.m. Paris time, which corresponds to 9:30 a.m. in New York.
Nanobiotix S.A. is launching an approximately €75 million (about $87 million) global follow-on equity offering, split between a U.S. ADS sale and an International Offering of ordinary shares and pre-funded warrants to qualified investors. All securities will be newly issued by the company via a capital increase without preferential subscription rights under prior shareholder delegations. The company may grant underwriters a 30-day option for up to 15% additional ADSs and has set a 90-day lock-up for itself and board members. Net proceeds are expected to be used mainly to advance its Nanoprimer and other platforms, with smaller portions for JNJ-1900 (NBTXR3) development and general corporate purposes, while management retains broad discretion over allocation. The company highlights potential dilution and trading volatility as key risks for existing shareholders.
Nanobiotix S.A. provides clinical and pipeline updates for its radioenhancer JNJ-1900 (NBTXR3) and Curadigm Nanoprimer platform in connection with an underwritten offering. The Phase 2 CONVERGE trial in unresectable stage 3 NSCLC reported early Part 1 data in seven patients, with an 85.7% objective response rate, 57.1% complete response rate and 100% disease control after chemoradiotherapy, JNJ-1900 and durvalumab, though the company cautions these preliminary results from a small cohort should not be seen as predictive.
The pivotal Phase 3 NANORAY-312 head and neck cancer trial, sponsored by Johnson & Johnson, was amended to remove an interim analysis and bring forward the final analysis at 335 events, with maintained endpoints and improved statistical power for progression-free survival at 92% and overall survival at 80%. Nanobiotix notes it may receive up to approximately $200 million in development and regulatory milestones from J&J over the next few years if head and neck and lung programs meet specified goals.
The company also highlights Curadigm Nanoprimer preclinical data showing that pretreatment in a mouse model increased systemic exposure and reduced liver clearance of lipid nanoparticle DNA immunotherapies, while decreasing hepatic toxicity and inflammatory responses. These findings, along with multiple ongoing collaborations and new patent filings, support further exploration of Curadigm with advanced intravenously delivered therapeutics.